FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956091219> ?p ?o ?g. }

• W2956091219 endingPage "3199" @default.
• W2956091219 startingPage "3199" @default.
• W2956091219 abstract "Abstract Background: While immune checkpoint inhibitors have revolutionized the treatment of multiple cancers, such therapies have had limited efficacy in ovarian cancer. We hypothesized that a lytic peptide could stimulate local immune response and enhance efficacy of checkpoint blockade. Here, we tested the effects of a synthetic lytic peptide targeting the luteinizing hormone receptor (LHRH-R), EP-100, on immune therapy in ovarian cancer models. Methods: We carried out series of in vitro (MTT assay, immunoblot analysis, cytokine array, and immune profiling assay) and in vivo (orthotopic mouse model) experiments to determine the biological effects of EP-100 monotherapy and its combination with checkpoint blockade, α-PD-L1. Results: We found that LHRH-R positive murine ovarian cancer cells (ID8, IG10, IF5, and 2C12) were sensitive to EP-100 and were specifically killed at low micromolar levels through LHRH-R. The in vivo syngeneic mouse models (ID8 and IG10) demonstrated that EP-100 reduced tumor volume, tumor weight, and ascites volume as a single agent. The greatest effects on tumor volume reduction and ascites volume were observed with the combination of EP-100 and α-PD-L1 antibody, indicating a potentially synergistic effect in vivo. Immune profiling of tumors showed that the population of CD8+ T cells, NK cells, dendritic cells, and macrophages were significantly increased in tumor and ascites treated with α-PD-L1, EP-100 and in the combination group. However, monocytic myeloid suppressor cells, B cells, and regulatory T cells were decreased in tumors treated with α-PD-L1, EP-100 and in the combination group. We found similar effects of EP-100 combination with α-PD-L1 antibody in ascites from each group. These data indicate that EP-100 promotes a tumor microenvironment that is favorable for immune response. In vitro cytokine arrays revealed that EP-100 induced IL-1α, IL-33, CCL20, VEGF, and LDLR secretion. Among them, we validated increasing Il-33 level following EP-100 treatment in vivo and in vitro and determined the specific biological role of CD8+ T cell activation with IL-33 gene silencing using siRNA and Cas9-CRISPR approaches. In addition, we found that CD8+ T cell expressed a low level of LHRH-R and had minimal direct effects from EP-100. Conclusion: These data demonstrate strong efficacy of EP-100 and checkpoint blockade therapy. Our results provide new directions to enhance the efficacy of immune therapies for ovarian cancer. Citation Format: Mark S. Kim, Shaolin Ma, Carola Leuschner, Sanghoon Lee, Robert L. Coleman, Anil K. Sood. Targeting LHRH-R to improve immune response in ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3199." @default.
• W2956091219 created "2019-07-12" @default.
• W2956091219 creator A5001967366 @default.
• W2956091219 creator A5009234043 @default.
• W2956091219 creator A5009442045 @default.
• W2956091219 creator A5012914572 @default.
• W2956091219 creator A5033319933 @default.
• W2956091219 creator A5087530060 @default.
• W2956091219 date "2019-07-01" @default.
• W2956091219 modified "2023-09-27" @default.
• W2956091219 title "Abstract 3199: Targeting LHRH-R to improve immune response in ovarian cancer" @default.
• W2956091219 doi "https://doi.org/10.1158/1538-7445.am2019-3199" @default.
• W2956091219 hasPublicationYear "2019" @default.
• W2956091219 type Work @default.
• W2956091219 sameAs 2956091219 @default.
• W2956091219 citedByCount "0" @default.
• W2956091219 crossrefType "journal-article" @default.
• W2956091219 hasAuthorship W2956091219A5001967366 @default.
• W2956091219 hasAuthorship W2956091219A5009234043 @default.
• W2956091219 hasAuthorship W2956091219A5009442045 @default.
• W2956091219 hasAuthorship W2956091219A5012914572 @default.
• W2956091219 hasAuthorship W2956091219A5033319933 @default.
• W2956091219 hasAuthorship W2956091219A5087530060 @default.
• W2956091219 hasConcept C121608353 @default.
• W2956091219 hasConcept C126322002 @default.
• W2956091219 hasConcept C150903083 @default.
• W2956091219 hasConcept C154317977 @default.
• W2956091219 hasConcept C202751555 @default.
• W2956091219 hasConcept C203014093 @default.
• W2956091219 hasConcept C207001950 @default.
• W2956091219 hasConcept C2777701055 @default.
• W2956091219 hasConcept C2780427987 @default.
• W2956091219 hasConcept C2780851360 @default.
• W2956091219 hasConcept C502942594 @default.
• W2956091219 hasConcept C55493867 @default.
• W2956091219 hasConcept C71924100 @default.
• W2956091219 hasConcept C86803240 @default.
• W2956091219 hasConcept C8891405 @default.
• W2956091219 hasConceptScore W2956091219C121608353 @default.
• W2956091219 hasConceptScore W2956091219C126322002 @default.
• W2956091219 hasConceptScore W2956091219C150903083 @default.
• W2956091219 hasConceptScore W2956091219C154317977 @default.
• W2956091219 hasConceptScore W2956091219C202751555 @default.
• W2956091219 hasConceptScore W2956091219C203014093 @default.
• W2956091219 hasConceptScore W2956091219C207001950 @default.
• W2956091219 hasConceptScore W2956091219C2777701055 @default.
• W2956091219 hasConceptScore W2956091219C2780427987 @default.
• W2956091219 hasConceptScore W2956091219C2780851360 @default.
• W2956091219 hasConceptScore W2956091219C502942594 @default.
• W2956091219 hasConceptScore W2956091219C55493867 @default.
• W2956091219 hasConceptScore W2956091219C71924100 @default.
• W2956091219 hasConceptScore W2956091219C86803240 @default.
• W2956091219 hasConceptScore W2956091219C8891405 @default.
• W2956091219 hasIssue "13_Supplement" @default.
• W2956091219 hasLocation W29560912191 @default.
• W2956091219 hasOpenAccess W2956091219 @default.
• W2956091219 hasPrimaryLocation W29560912191 @default.
• W2956091219 hasRelatedWork W1996150995 @default.
• W2956091219 hasRelatedWork W2886039816 @default.
• W2956091219 hasRelatedWork W3006273887 @default.
• W2956091219 hasRelatedWork W3115086337 @default.
• W2956091219 hasRelatedWork W3216801484 @default.
• W2956091219 hasRelatedWork W4206840735 @default.
• W2956091219 hasRelatedWork W4241449638 @default.
• W2956091219 hasRelatedWork W4281723870 @default.
• W2956091219 hasRelatedWork W4293102479 @default.
• W2956091219 hasRelatedWork W4360983034 @default.
• W2956091219 hasVolume "79" @default.
• W2956091219 isParatext "false" @default.
• W2956091219 isRetracted "false" @default.
• W2956091219 magId "2956091219" @default.
• W2956091219 workType "article" @default.